

FAX TRANSMISSION

MUETING, RAASCH & GEBHARDT, P.A.

203 Textile Building
119 North Fourth Street
Minneapolis, MN 55401
Fax: 612/305-1228

Patent, Trademark & Copyright Attorneys

Date: 4 December 2002

To: United States Patent and Trademark Office
Group Art Unit 1642
703/746-9195

From: Ann M. Mueeting

Pages: 6 [Including cover]

Subject: RESENDING ATTACHED FAX AS COPY OF MARKED UP
FILING RECEIPT WAS INADVERTENTLY OMITTED.

PRIVILEGED ATTORNEY/CLIENT INFORMATION

This message contains attorney/client privileged communications and confidential business information that is intended for use only by the individual or company to whom it is addressed. Disclosure, interception, copying or any other use of this message by anyone other than the intended recipient, or the employee or agent of the intended recipient, is strictly prohibited and may be a violation of Federal and State law. If you receive this facsimile by mistake, please notify the sender by telephone (collect calls accepted) and return the original documents to the sender at Mueeting & Raasch, 203 Textile Building, 119 North Fourth Street, Minneapolis, MN 55401. Mueeting & Raasch will pay all reasonable costs for return postage.

PATENT
Docket No. 110.012701

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): MCCARTHY et al.)
Serial No.: 09/937,076)
Confirmation No.: 4527)
Filed: March 27, 2002)
For: METHODS OF USE OF β 1-INTEGRIN INHIBITORS

Group Art Unit: 1642
Examiner: Unknown

FACSIMILE TRANSMISSION TO THE PTO

Assistant Commissioner for Patents
Attn: Examiner Unknown
Washington, D.C. 20231

FAX NUMBER: 703/746-9195
Total Pages (including cover page): 33
Time: 2:55 p.m. (Central Time)
(Transmission must be complete by
midnight eastern time.)

The following papers are being transmitted to the Patent and Trademark Office by facsimile transmission: A Request for Corrected Filing Receipt (2 pgs.), A Copy of Filing Receipt with marked correction (2 pgs.).

X Small Entity Status is entitled to be asserted in the above-identified application.

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895.

Mueting, Raasch & Gebhardt, P.A.
Customer Number: 26813



26813

PATENT TRADEMARK OFFICE

Dec. 3, 2002
Date

By: Ann M. Mueting
Attorney: Ann M. Mueting
Reg. No. 33,977
Direct Dial (612)305-1217

CERTIFICATE UNDER 37 C.F.R. §1.8: The undersigned hereby certifies that this Facsimile Cover Sheet and the paper(s), as described hereinabove, are being transmitted by facsimile in accordance with 37 CFR §1.6(d) to the Patent and Trademark Office addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on this 3 day of December, 2002, at 2:55 p.m. (Central Time).

12-3-02
Date

Signature: Sandy Truehart
Name: SANDY TRUEHART

If you do not receive all pages, please contact us at (612)305-1220 (ph) or (612)305-1228 (fax).

PATENT
Attorney Docket No. 110.01270101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	James B. McCarthy et al.)	Group Art Unit:	1642
)		
Serial No.:	09/937,076)	Examiner:	unknown
Confirmation No.:	4527)		
)		
Filed:	March 27, 2002)		
)		
For:	<u>METHODS OF USE OF β1-INTEGRIN INHIBITORS</u>			

REQUEST FOR CORRECTED FILING RECEIPT

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, D.C. 20231

Sir:

The Filing Receipt received from the U.S. Patent and Trademark Office in connection with the above-identified application, indicates the Domestic Priority data as claimed by applicant is not consistent with PTO records.

Please amend the Domestic Priority data to read as follows:

This Application is a 371 of PCT/US00/07680 03/22/2000
which claims benefit of 60/125,634 03/22/1999 and
60/167,538 11/24/99.

A copy of the Filing Receipt with this correction marked in red is enclosed. Applicants respectfully request a corrected Filing Receipt.

Please charge any additional fees or credit overpayment to Deposit Account No. 13-4895.

Request for Corrected Filing Receipt

Page 2

Applicant(s): James B. McCarthy et al.
Serial No.: 09/937,076
Confirmation No.: 4527
Filed: March 27, 2002
International Filing Date: March 22, 2000
For: METHODS OF USE OF β 1-INTEGRIN INHIBITORS

If the Examiner has any questions regarding this submission, please contact Applicants' Representative at the below-listed telephone number.

CERTIFICATE UNDER 37 CFR §1.8:

The undersigned hereby certifies that this paper is being transmitted by facsimile in accordance with 37 CFR §1.6(d) to the Patent and Trademark Office, addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on this 3 day of December, 2002, at 2:55 p.m. (Central Time).

By: Sandy Truehart
Name: SANDY TRUEHART

Dec. 3, 2002
Date

AMM/sjt

Respectfully submitted for

JAMES B. MCCARTHY ET AL.

By
Mueting, Raasch & Gebhardt, P.A.
P.O. Box 581415
Minneapolis, MN 55458-1415
Phone: (612)305-1220
Facsimile: (612)305-1228
Customer Number 26813



26813

PATENT TRADEMARK OFFICE

By: Ann M. Mueting
Ann M. Mueting
Reg. No. 33,977
Direct Dial (612)305-1217

SKD



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/937,076	03/27/2002	1642	915	110.01270101	16	40	9

4/19/02 1 year Status Check

CONFIRMATION NO. 4527

26813

MUETING, RAASCH & GEBHARDT, P.A.

P.O. BOX 581415

MINNEAPOLIS, MN 55458

FILING RECEIPT



OC00000008578737

Date Mailed: 08/08/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

James B. McCarthy, Minneapolis, MN;
William J. Mileski, Galveston, TX;
Gordon A. Jamieson Jr., Cincinnati, OH;
Walter C. Low, Shorewood, MN;
Ronald J. Sawchuk, New Brighton, MN;
Leo T. Furcht, Minneapolis, MN;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/US00/07680 03/22/2000
WHICH CLAIMS BENEFIT OF 60/125,634 03/22/1999

~~THIS APPLICATION 09/937,076 AND~~

~~CLAIMS BENEFIT OF 60/167,538 11/24/1999 *~~

(*)Data provided by applicant is not consistent with PTO records.

Foreign Applications

Projected Publication Date: Not Applicable, filed prior to November 29,2000

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

RECEIVED

AUG 15 2002

MUETING & RAASCH

Title

Methods of use of beta1-integrin inhibitors

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).